The post Gasparino Mocks XRP Holders: How Much Did Brad Garlinghouse Profit Off of Your ‘Idiocy’? appeared on BitcoinEthereumNews.com. “Cult of bagholders” XRP’The post Gasparino Mocks XRP Holders: How Much Did Brad Garlinghouse Profit Off of Your ‘Idiocy’? appeared on BitcoinEthereumNews.com. “Cult of bagholders” XRP’

Gasparino Mocks XRP Holders: How Much Did Brad Garlinghouse Profit Off of Your ‘Idiocy’?

  • “Cult of bagholders”
  • XRP’s underwhelming year 

On Sunday, Fox Business Network Senior Correspondent Charles Gasparino started feuding with the “XRP Army”once again.

In a series of blistering posts on X (formerly Twitter), Gasparino took aim at the intelligence of retail investors holding the token. The controversial host has questioned whether they realize they are ostensibly serving as exit liquidity for Ripple executives.

The latest flare-up began when Gasparino responded to a user regarding the financial logic of holding the asset. “Setting aside the idiocy of you holding XRP thinking you’re getting rich,” Gasparino wrote, “how much did Brad Garlinghouse and the gang profit off of your idiocy? Sad Ha!”

The Fox News host has doubled down on the narrative in another tweet. “Don’t you wish [SEC Chair] Jay [Clayton] made Ripple people disclose how much money they made on XRP while you lost all that money?” he taunted. “You really make this easy.”

“Cult of bagholders”

Gasparino, who has previously claimed credit for putting the XRP community “on the map in a mainstream way,” has spent the better part of late 2025 and early 2026 sparring with community stalwarts. 

You Might Also Like

The television personality has frequently characterized the community as a “cult of bagholders,” engaging in bizarre, specific spats with prominent accounts. In interactions with XRP influencer Mr. Huber (@Leerzeit), whom Gasparino refers to as “Mr. Germany,” the host mocked the user’s purchasing power relative to the token’s performance.

“Whenever Mr. Germany doesn’t have money for a bratwurst or a little schnitzel because he lost it all on $XRP this clown shows up on my timeline,” Gasparino tweeted in late November. “Sorry this isn’t helping XRP cult of bagholders rich; as far as management’s concerned, they’ve already cashed out.”

The vitriol comes amidst a period of price volatility for the asset, which Gasparino described recently as “flailing” and “getting absolutely crushed.”

The XRP Army frequently accuses the journalist of bias or carrying water for SEC interests. Gasparino maintains his role is that of a reality checker. 

XRP’s underwhelming year 

2025 was supposed to be the “golden year” for XRP. Following the SEC settlement in May, the token staged a massive rally, hitting an all-time high of roughly $3.65 in July. The euphoria was deafening, with predictions of double-digit prices flooding the timeline.

However, since that July peak, XRP has bled out nearly 45% of its value, languishing around the $2.00 range through late 2025 and into early 2026.

Gasparino has seized on this “round-trip” price action to characterize the community as “bagholders.” Back in November, Gasparino tweeted that XRP was |getting absolutely crushed.”

Source: https://u.today/gasparino-mocks-xrp-holders-how-much-did-brad-garlinghouse-profit-off-of-your-idiocy

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.91
$1.91$1.91
-0.22%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26